196 related articles for article (PubMed ID: 19956980)
1. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Mattiuzzi GN; Cortes J; Alvarado G; Verstovsek S; Koller C; Pierce S; Blamble D; Faderl S; Xiao L; Hernandez M; Kantarjian H
Support Care Cancer; 2011 Jan; 19(1):19-26. PubMed ID: 19956980
[TBL] [Abstract][Full Text] [Related]
2. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
[TBL] [Abstract][Full Text] [Related]
3. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI; Pagliuca A; Kibbler CC; Glasmacher A; Heussel CP; Kantecki M; Miller PJ; Ribaud P; Schlamm HT; Solano C; Cook G;
Br J Haematol; 2011 Nov; 155(3):318-27. PubMed ID: 21880032
[TBL] [Abstract][Full Text] [Related]
8. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity.
Whittle AM; Ali S
Int J Lab Hematol; 2008 Apr; 30(2):173-4. PubMed ID: 18333850
[No Abstract] [Full Text] [Related]
10. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era.
Keighley CL; Manii P; Larsen SR; van Hal S
Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):213-217. PubMed ID: 27830376
[TBL] [Abstract][Full Text] [Related]
12. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.
Cadena J; Levine DJ; Angel LF; Maxwell PR; Brady R; Sanchez JF; Michalek JE; Levine SM; Restrepo MI
Am J Transplant; 2009 Sep; 9(9):2085-91. PubMed ID: 19645709
[TBL] [Abstract][Full Text] [Related]
13. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
[TBL] [Abstract][Full Text] [Related]
14. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.
Gergis U; Markey K; Greene J; Kharfan-Dabaja M; Field T; Wetzstein G; Schell MJ; Huang Y; Anasetti C; Perkins J
Bone Marrow Transplant; 2010 Apr; 45(4):662-7. PubMed ID: 19684623
[TBL] [Abstract][Full Text] [Related]
16. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
17. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole prophylaxis in hematologic cancer.
van Nieuwkoop C; van Dissel JT
N Engl J Med; 2007 May; 356(21):2215; author reply 2215-8. PubMed ID: 17526089
[No Abstract] [Full Text] [Related]
19. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
20. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Lazzaro C
Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
